Aptevo Therapeutics Inc.

NASDAQ: APVO · Real-Time Price · USD
1.99
-0.05 (-2.45%)
At close: Aug 15, 2025, 3:02 PM

Aptevo Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a 3.11M 12.29M
Cost of Revenue
352K 17.11M 17.88M 18.99M
Gross Profit
-352K -567K -14.77M -6.7M
Operating Income
-24.6M -28.88M -28.64M -21.4M
Interest Income
n/a n/a n/a n/a
Pretax Income
-24.13M -18.65M 7.01M -29.41M
Net Income
-24.13M -17.41M 8.03M -27.31M
Selling & General & Admin
10.22M 11.77M 13.87M 14.7M
Research & Development
14.38M 17.11M 17.88M 18.99M
Other Expenses
-352K -17.11M -1.53M -8.01M
Operating Expenses
24.25M 28.31M 31.75M 33.69M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
24.6M 28.88M 31.75M 33.69M
Income Tax Expense
n/a n/a n/a -2.1M
Shares Outstanding (Basic)
13.81K 375.76 156.64 143.98
Shares Outstanding (Diluted)
13.81K 375.76 156.72 143.98
EPS (Basic)
-1.75K -46.34K 51.24K -197.65K
EPS (Diluted)
-1.75K -46.34K 51.22K -197.65K
EBITDA
-23.78M -28.31M -27.74M -20.26M
EBIT
-24.13M -28.88M -28.64M -21.4M
Depreciation & Amortization
352K 567K 901K 1.14M